Clinical completed trials
MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS)
This study will evaluate the safety of injecting MSCs in people with multiple sclerosis. The proposed therapeutic strategy is to modulate or suppress the aggressive immune process, to protect axons and neurons from degeneration, and to enhance repair and facilitate remyelination.
|
Clinical indication Multiple sclerosis |
Disease area Neurology |
Cell type ASC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial Yes |
Transgene No |
Activation/differentiation No |
|
Trial phase 1/2 |
Recruitment target 12 |
Year trial started 2015 |
Trial status Completed |
|
Clinical trial ID |
Website - |
Principal investigator : Michel Clanet (Toulouse UNiversity Hospital)
ECELLFrance activity : Cell production (ATMP)
ECELLFrance contact : Olivier Detante
Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing (Ortho-CT1)
The expected results are to obtain bone consolidation thus healing of delayed union or non-union using proposed IMP based on pluripotent MSCs expanded in a GMP facility and mixed with granulated biphasic calcium phosphate in the surgical setting before implantation.
|
Clinical indication Delayed-union or non-union fractures of long bones |
Disease area Musculoskeletal |
Cell type BMSC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial Yes |
Transgene No |
Activation/differentiation No |
|
Trial phase 2 |
Recruitment target 30 |
Year trial started 2013 |
Trial status Completed |
|
Clinical trial ID |
Website - |
Principal investigator : Enrique Gomez-Barrena (Universidad Autonoma de Madrid)
ECELLFrance activities : Cell production (ATMP), gene modification/transfection, cell potency/QC, patient immunomonitoring, coordination (Luc Sensebé)
ECELLFrance contact : Hélène Rouard
Intravenous stem cell therapy for ischemic stroke (ISIS)
The main objective of the study is to evaluate feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells for patients presenting an ischemic stroke.
|
Clinical indication Stroke |
Disease area Neurology |
Cell type BMSC |
Autologous/allogeneic Autologous |
|
Route of administration Systemic |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 2b |
Recruitment target 31 |
Year trial started 2012 |
Trial status Completed |
|
Clinical trial ID |
Website - |
Principal investigator : Olivier Detante (ECELLFrance)
ECELLFrance activities : Cell production (ATMP), coordination (Olivier Detante)
ECELLFrance contact : Olivier Detante
ADIPOSE CELL DERIVED REGENRATIVE ENDOTHELIAL ANGIOGENIC MEDICINE (ACELLDREAM)
The main purpose of this study is to evaluate the efficacy of regenerative therapy with expanded adipose derived stromal/stem cells, administered intramuscularly in patients with critical leg ischemia.
|
Clinical indication Critical limb ischemia |
Disease area Cardiology/Vascular |
Cell type ASC |
Autologous/allogeneic Autologous |
|
Route of administration Intramuscular |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase Phase 1/2 |
Recruitment target 18 |
Year trial started 2017 |
Trial status Completed |
|
Clinical trial ID |
Website - |
Principal investigator : Jérome Roncalli (Toulouse University hospital, France)
ECELLFrance activities : cell production (ATMP), cell potency/QC
ECELLFrance contact : Louis Casteilla
AUTOLOGOUS ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS (ASC) IN THE TREATMENT OF MILD TO MODERATE OSTEOARTHRITIS (ADIPOA)
To evaluate the safety of a single injection of autologous adipose derived mesenchymal stromal cells in the treatment of severe osteoarthritis of the knee joint (ADIPOA).
This study is designed to determine the safety and efficacy of a single injection of autologous adipose derived mesenchymal stromal cells (ASCs) on patients with severe osteoarthritis of the knee (OA)
|
Clinical indication Osteoarthritis |
Disease area Musculoskeletal |
Cell type ASC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 1/2 |
Recruitment target 18 |
Year trial started 2012 |
Trial status Completed |
|
Clinical trial ID |
Website - |
Principal investigator : Christian Jorgensen (ECELLFrance)
ECELLFrance activities : Cell production (ATMP), coordination (Christian Jorgensen)
ECELLFrance contact : Christian Jorgensen
Mesenchymal Stem Cells and Myocardial Ischemia (MESAMI)
This study purpose is to evaluate the safety of injecting MSCs directly into the heart to repair and restore heart function in people who have had a heart attack and who have chronic myocardial ischemia with heart failure.
|
Clinical indication Chronic Myocardial Ischemia |
Disease area Cardiology/Vascular |
Cell type BMSC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 1/2 |
Recruitment target 10 |
Year trial started 2009 |
Trial status Completed |
|
Clinical trial ID |
Website - |
Principal investigator : Jérome Roncalli (Toulouse University hospital, France)
ECELLFrance activity : Cell production (ATMP)
ECELLFrance contact : Louis Casteilla